Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

BAT-8006 is under clinical development by Bio-Thera Solutions and currently in Phase II for Epithelial Ovarian Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Cytoreductive surgery, whether performed as the initial treatment or following neoadjuvant chemotherapy (NACT) for advanced ...

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National ...

tomorrow t20 world cup match Phase II clinical study of intraperitoneal chemotherapy for advanced epithelial ovarian cancer was presented on poster The “upgraded version” of PD-1 inhibitor is coming: ...

Raja Ranl result The National Development and Reform Commission issued the latest document to restrict and eliminate a number of backward pharmaceutica ...

Tabonline login Phase II clinical study of intraperitoneal chemotherapy for advanced epithelial ovarian cancer was presented on poster With an additional capital increase of US$7.223 million, why is ...